Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Precision BioSciences Inc.

www.precisionbiosciences.com

Latest From Precision BioSciences Inc.

Kite Readies A Second CAR-T For Filing As CD19 Competition Grows

The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year. 

Clinical Trials Cancer

ASH First Look: CAR-T Therapies Against BCMA, CD19 And More

CAR-T therapies from Janssen, Celgene and others will get a lot of attention at the annual hematology meeting, including candidates with novel constructs and targets. 

Clinical Trials Research and Development Strategies

Venture Funding Deals: Recent Rounds For Gene-Editing Plays Top $300m

Gene-editing focused start-ups Beam Therapeutics, Gracell, Snipr Biome and Precision Biosciences raised a total of $310m in financings in February and March. For other recent venture funding deals... 
Deals Financing

Finance Watch: Genfit Launches IPO To Expand US Presence Ahead Of Phase III NASH Results

Public Company Edition: COO Dean Hum talked to Scrip about Genfit's IPO strategy – which wasn't just about raising money – as it anticipates Phase III elafibranor data later this year. Also, Precision BioSciences launches its IPO, while Myokardia, Dermira and Tricida lead new public company financings.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Cardiovascular
  • Hepatic (Liver)
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Precision BioSciences Inc.
  • Senior Management
  • Matthew Kane, CEO
    Abid Ansari, CFO
    Derek Jantz, PhD, CSO
    David Thomson, PhD, Chief Dev. Officer
    Jeff Smith, PhD, CTO
    Christopher H Heery, MD, CMO
    David Thomson, PhD, COO
  • Contact Info
  • Precision BioSciences Inc.
    Phone: (919) 314-5512
    302 East Pettigrew St., Dibrell Bldg.
    Ste. A-100
    Durham, NC 27701
    USA
UsernamePublicRestriction

Register